Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -51.60M
March 31, 2026 277.40M
December 31, 2025 -211.20M
September 30, 2025 -98.90M
June 30, 2025 -52.50M
March 31, 2025 -65.10M
December 31, 2024 -168.70M
September 30, 2024 1.748B
June 30, 2024 375.80M
March 31, 2024 -154.30M
December 31, 2023 115.80M
September 30, 2023 -53.80M
June 30, 2023 -76.60M
March 31, 2023 -749.50M
December 31, 2022 1.784B
September 30, 2022 -115.00M
June 30, 2022 -82.10M
March 31, 2022 -66.90M
December 31, 2021 -219.10M
September 30, 2021 -118.20M
June 30, 2021 -16.80M
March 31, 2021 236.30M
December 31, 2020 -22.30M
September 30, 2020 -58.70M
June 30, 2020 -74.50M
Date Value
March 31, 2020 -145.60M
December 31, 2019 -114.50M
September 30, 2019 -176.90M
June 30, 2019 -158.40M
March 31, 2019 -75.60M
December 31, 2018 -175.60M
September 30, 2018 -302.10M
June 30, 2018 -303.80M
March 31, 2018 -428.90M
December 31, 2017 -228.20M
September 30, 2017 -126.90M
June 30, 2017 -464.70M
March 31, 2017 -164.10M
December 31, 2016 -646.80M
September 30, 2016 -5.781B
June 30, 2016 -1.091B
March 31, 2016 -160.00M
December 31, 2015 -952.20M
September 30, 2015 -372.60M
June 30, 2015 -190.90M
March 31, 2015 -87.50M
December 31, 2014 -154.70M
September 30, 2014 -321.20M
June 30, 2014 -118.10M
March 31, 2014 -201.20M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Pacira Biosciences, Inc. 11.76M
Eli Lilly & Co. -15.40B
Pfizer Inc. 2.106B
Merck & Co., Inc. -5.602B
Bristol Myers Squibb Co. -1.614B